#USA #New York #Medtronic #Pulnovo Medical #PADN System

Pulnovo Medical's Strategic Investment from Medtronic

Pulnovo Medical, a leader in innovative therapies for treating pulmonary hypertension and heart failure, has recently announced a successful closing of a $100 million financing round. This funding round was oversubscribed and led by Medtronic, one of the largest medical technology companies in the world. Established investors like EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures also participated in this round. New investors, including HSG (formerly Sequoia China) and other prominent global entities, have joined in supporting Pulnovo's mission to revolutionize heart and lung care.

This stage of funding represents a critical milestone in Pulnovo's journey, signaling robust confidence from both strategic and institutional investors in the company's innovative technology and clinical progress. Furthermore, the announcement also revealed a commercial agreement between Pulnovo and Medtronic, setting the stage for future marketing opportunities that leverage Medtronic’s extensive market experience and existing commercial synergies.

The Impact of the Pulmonary Artery Denervation (PADN) System

At the heart of Pulnovo's innovation is its proprietary Pulmonary Artery Denervation (PADN) System. This minimal-invasive therapy addresses a central mechanism of cardiopulmonary diseases, showing significant clinical benefits such as improvements in functional capacity and patient outcomes. To date, Pulnovo has conducted around 1,500 PADN procedures globally and gained regulatory approvals in seven countries, further strengthening its international presence.

The company is actively advancing marketing initiatives in the European Union, the Middle East, and China. In the U.S., Pulnovo received the FDA's Breakthrough Device designation and initiated two fully approved studies under an Investigational Device Exemption (IDE), both led by Dr. Gregg Stone, a prominent Professor at Mount Sinai.

Building a Sustainable Growth Model

Cynthia Chen, the Chair and President of Pulnovo Medical, expressed that by combining industry expertise with long-term capital, Pulnovo is developing a scalable growth model focused on their proprietary innovations and strategic partnerships within the healthcare ecosystem. This financing phase marks a pivotal transition from a product-centric model to a fully integrated global platform. The commitment remains strong to provide significant innovations to patients worldwide while enhancing clinical and technological capabilities.

Strengthening Global Collaborations

The recent financing not only bolsters Pulnovo's financial standing but also enhances its strategic collaborations with industry and capital partners, enabling accelerated clinical development and execution of global regulatory strategies. The proceeds will be utilized to support ongoing clinical development, international marketing efforts, and further investments in the company’s core technological platform.

To drive this growth, Andre Xiao has joined Pulnovo as the Chief Strategy Officer, where he will lead global financing and strategy. With an extensive background in healthcare investments and experience with major investment firms like Citadel and Millennium Management, Andre aims to strengthen Pulnovo's ties to global capital markets, facilitating the company's next growth phase.

About PADN Therapy and Clinical Trials

Pulnovo’s PADN System is the first in its class of minimal-invasive therapies, designed to modulate the overactive sympathetic nervous activity that contributes to the remodeling of pulmonary vessels and the progression of cardiopulmonary conditions. Due to its focus on a central disease mechanism, PADN has demonstrated clinically meaningful outcomes in global studies, improving functional capacity and reducing major adverse clinical events.

The therapy has been recognized in multiple international clinical guidelines and is mentioned in seven clinical guidelines, highlighting its significance in the management of pulmonary hypertension since its inclusion in the European Society of Cardiology and European Respiratory Society guidelines.

Clinical trials are ongoing in various regions, including near completion studies in Europe and Asia, alongside recently initiated trials like the PULSE-LHD IDE study in the United States. These studies are expected to reinforce the clinical evidence for PADN and underline the therapy's potential to address significant unmet medical needs in heart failure and related conditions.

Introduction to Pulnovo Medical

Pulnovo Medical is an innovative medical technology company focused on developing interventional therapies for pulmonary hypertension and heart failure. With a commitment to clinical benefit, the company is dedicated to advancing groundbreaking solutions based on its proprietary technology platform, emphasizing global clinical development and marketing to improve patient treatment outcomes worldwide.